An autosomal dominant inherited disorder (with a high frequency of spontaneous mutations) that features developmental changes in the nervous system, muscles, bones, and skin, most notably in tissue derived from the embryonic NEURAL CREST. Multiple hyperpigmented skin lesions and subcutaneous tumors are the hallmark of this disease. Peripheral and central nervous system neoplasms occur frequently, especially OPTIC NERVE GLIOMA and NEUROFIBROSARCOMA. NF1 is caused by mutations which inactivate the NF1 gene (GENES, NEUROFIBROMATOSIS 1) on chromosome 17q. The incidence of learning disabilities is also elevated in this condition. (From Adams et al., Principles of Neurology, 6th ed, pp1014-18) There is overlap of clinical features with NOONAN SYNDROME in a syndrome called neurofibromatosis-Noonan syndrome. Both the PTPN11 and NF1 gene products are involved in the SIGNAL TRANSDUCTION pathway of Ras (RAS PROTEINS).
An autosomal dominant disorder characterized by a high incidence of bilateral acoustic neuromas as well as schwannomas (NEURILEMMOMA) of other cranial and peripheral nerves, and other benign intracranial tumors including meningiomas, ependymomas, spinal neurofibromas, and gliomas. The disease has been linked to mutations of the NF2 gene (GENES, NEUROFIBROMATOSIS 2) on chromosome 22 (22q12) and usually presents clinically in the first or second decade of life.
Tumor suppressor genes located on the long arm of human chromosome 17 in the region 17q11.2. Mutation of these genes is thought to cause NEUROFIBROMATOSIS 1, Watson syndrome, and LEOPARD syndrome.
Tumor suppressor genes located on the long arm of human chromosome 22. Mutation or loss of these genes causes NEUROFIBROMATOSIS 2.
A group of disorders characterized by an autosomal dominant pattern of inheritance with high rates of spontaneous mutation and multiple neurofibromas or neurilemmomas. NEUROFIBROMATOSIS 1 (generalized neurofibromatosis) accounts for approximately 95% of cases, although multiple additional subtypes (e.g., NEUROFIBROMATOSIS 2, neurofibromatosis 3, etc.) have been described. (From Neurochirurgie 1998 Nov;44(4):267-72)
A protein found most abundantly in the nervous system. Defects or deficiencies in this protein are associated with NEUROFIBROMATOSIS 1, Watson syndrome, and LEOPARD syndrome. Mutations in the gene (GENE, NEUROFIBROMATOSIS 1) affect two known functions: regulation of ras-GTPase and tumor suppression.
A membrane protein homologous to the ERM (Ezrin-Radixin-Moesin) family of cytoskeleton-associated proteins which regulate physical properties of membranes. Alterations in neurofibromin 2 are the cause of NEUROFIBROMATOSIS 2.
A type of neurofibroma manifesting as a diffuse overgrowth of subcutaneous tissue, usually involving the face, scalp, neck, and chest but occasionally occurring in the abdomen or pelvis. The tumors tend to progress, and may extend along nerve roots to eventually involve the spinal roots and spinal cord. This process is almost always a manifestation of NEUROFIBROMATOSIS 1. (From Adams et al., Principles of Neurology, 6th ed, p1016; J Pediatr 1997 Nov;131(5):678-82)
A moderately firm, benign, encapsulated tumor resulting from proliferation of SCHWANN CELLS and FIBROBLASTS that includes portions of nerve fibers. The tumors usually develop along peripheral or cranial nerves and are a central feature of NEUROFIBROMATOSIS 1, where they may occur intracranially or involve spinal roots. Pathologic features include fusiform enlargement of the involved nerve. Microscopic examination reveals a disorganized and loose cellular pattern with elongated nuclei intermixed with fibrous strands. (From Adams et al., Principles of Neurology, 6th ed, p1016)
Light brown pigmented macules associated with NEUROFIBROMATOSIS and Albright's syndrome (see FIBROUS DYSPLASIA, POLYOSTOTIC).
Glial cell derived tumors arising from the optic nerve, usually presenting in childhood.
Neoplasms which arise from nerve sheaths formed by SCHWANN CELLS in the PERIPHERAL NERVOUS SYSTEM or by OLIGODENDROCYTES in the CENTRAL NERVOUS SYSTEM. Malignant peripheral nerve sheath tumors, NEUROFIBROMA, and NEURILEMMOMA are relatively common tumors in this category.
A neoplasm that arises from SCHWANN CELLS of the cranial, peripheral, and autonomic nerves. Clinically, these tumors may present as a cranial neuropathy, abdominal or soft tissue mass, intracranial lesion, or with spinal cord compression. Histologically, these tumors are encapsulated, highly vascular, and composed of a homogenous pattern of biphasic fusiform-shaped cells that may have a palisaded appearance. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp964-5)
Benign and malignant neoplasms that arise from the optic nerve or its sheath. OPTIC NERVE GLIOMA is the most common histologic type. Optic nerve neoplasms tend to cause unilateral visual loss and an afferent pupillary defect and may spread via neural pathways to the brain.
A benign SCHWANNOMA of the eighth cranial nerve (VESTIBULOCOCHLEAR NERVE), mostly arising from the vestibular branch (VESTIBULAR NERVE) during the fifth or sixth decade of life. Clinical manifestations include HEARING LOSS; HEADACHE; VERTIGO; TINNITUS; and FACIAL PAIN. Bilateral acoustic neuromas are associated with NEUROFIBROMATOSIS 2. (From Adams et al., Principles of Neurology, 6th ed, p673)
Neoplasms which arise from peripheral nerve tissue. This includes NEUROFIBROMAS; SCHWANNOMAS; GRANULAR CELL TUMORS; and malignant peripheral NERVE SHEATH NEOPLASMS. (From DeVita Jr et al., Cancer: Principles and Practice of Oncology, 5th ed, pp1750-1)
A malignant tumor that arises from small cutaneous nerves, is locally aggressive, and has a potential for metastasis. Characteristic histopathologic features include proliferating atypical spindle cells with slender wavy and pointed nuclei, hypocellular areas, and areas featuring organized whorls of fibroblastic proliferation. The most common primary sites are the extremities, retroperitoneum, and trunk. These tumors tend to present in childhood, often in association with NEUROFIBROMATOSIS 1. (From DeVita et al., Cancer: Principles & Practice of Oncology, 5th ed, p1662; Mayo Clin Proc 1990 Feb;65(2):164-72)
Benign and malignant neoplasms that arise from one or more of the twelve cranial nerves.
Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms.
A relatively common neoplasm of the CENTRAL NERVOUS SYSTEM that arises from arachnoidal cells. The majority are well differentiated vascular tumors which grow slowly and have a low potential to be invasive, although malignant subtypes occur. Meningiomas have a predilection to arise from the parasagittal region, cerebral convexity, sphenoidal ridge, olfactory groove, and SPINAL CANAL. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2056-7)
Multi-channel hearing devices typically used for patients who have tumors on the COCHLEAR NERVE and are unable to benefit from COCHLEAR IMPLANTS after tumor surgery that severs the cochlear nerve. The device electrically stimulates the nerves of cochlea nucleus in the BRAIN STEM rather than the inner ear as in cochlear implants.
A congenital or acquired protrusion of the meninges, unaccompanied by neural tissue, through a bony defect in the skull or vertebral column.
A focal malformation resembling a neoplasm, composed of an overgrowth of mature cells and tissues that normally occur in the affected area.
A pathologic entity characterized by deossification of a weight-bearing long bone, followed by bending and pathologic fracture, with inability to form normal BONY CALLUS leading to existence of the "false joint" that gives the condition its name. (Dorland, 27th ed)
A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.
Neuroglial cells of the peripheral nervous system which form the insulating myelin sheaths of peripheral axons.
Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These disorders may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.
A genetically heterogeneous, multifaceted disorder characterized by short stature, webbed neck, ptosis, skeletal malformations, hypertelorism, hormonal imbalance, CRYPTORCHIDISM, multiple cardiac abnormalities (most commonly including PULMONARY VALVE STENOSIS), and some degree of INTELLECTUAL DISABILITY. The phenotype bears similarities to that of TURNER SYNDROME that occurs only in females and has its basis in a 45, X karyotype abnormality. Noonan syndrome occurs in both males and females with a normal karyotype (46,XX and 46,XY). Mutations in a several genes (PTPN11, KRAS, SOS1, NF1 and RAF1) have been associated the the NS phenotype. Mutations in PTPN11 are the most common. LEOPARD SYNDROME, a disorder that has clinical features overlapping those of Noonan Syndrome, is also due to mutations in PTPN11. In addition, there is overlap with the syndrome called neurofibromatosis-Noonan syndrome due to mutations in NF1.
Facial neoplasms are abnormal growths or tumors that develop in the facial region, which can be benign or malignant, originating from various cell types including epithelial, glandular, connective tissue, and neural crest cells.
The occurrence in an individual of two or more cell populations of different chromosomal constitutions, derived from a single ZYGOTE, as opposed to CHIMERISM in which the different cell populations are derived from more than one zygote.
Developmental bone diseases are a category of skeletal disorders that arise from disturbances in the normal growth and development of bones, including abnormalities in size, shape, structure, or composition, which can lead to various musculoskeletal impairments and deformities.
A specific pair of GROUP G CHROMOSOMES of the human chromosome classification.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Autosomal dominant, congenital disorder characterized by localized hypomelanosis of the skin and hair. The most familiar feature is a white forelock presenting in 80 to 90 percent of the patients. The underlying defect is possibly related to the differentiation and migration of melanoblasts, as well as to defective development of the neural crest (neurocristopathy). Piebaldism may be closely related to WAARDENBURG SYNDROME.
A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298)
Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.
Benign and malignant neoplastic processes that arise from or secondarily involve the meningeal coverings of the brain and spinal cord.
A SOMATOSTATIN-secreting tumor derived from the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS). It is also found in the INTESTINE. Somatostatinomas are associated with DIABETES MELLITUS; CHOLELITHIASIS; STEATORRHEA; and HYPOCHLORHYDRIA. The majority of somatostatinomas have the potential for METASTASIS.
The loss of calcium salts from bones and teeth. Bacteria may be responsible for this occurrence in teeth. Old age may be a factor contributing to calcium loss, as is the presence of diseases such as rheumatoid arthritis.
Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.
Pigmentation disorders are conditions that affect the production or distribution of melanin, the pigment responsible for skin, hair, and eye color, leading to changes in the color of these bodily features.
A blue-red, extremely painful vascular neoplasm involving a glomeriform arteriovenous anastomosis (glomus body), which may be found anywhere in the skin, most often in the distal portion of the fingers and toes, especially beneath the nail. It is composed of specialized pericytes (sometimes termed glomus cells), usually in single encapsulated nodular masses which may be several millimeters in diameter (From Stedman, 27th ed). CHEMODECTOMA, a tumor of NEURAL CREST origin, is also sometimes called a glomus tumor.
The X-shaped structure formed by the meeting of the two optic nerves. At the optic chiasm the fibers from the medial part of each retina cross to project to the other side of the brain while the lateral retinal fibers continue on the same side. As a result each half of the brain receives information about the contralateral visual field from both eyes.
Tumors or cancer of the ADRENAL GLANDS.
Tumors or cancer of the SKIN.
Thoracic neoplasms are a broad category of abnormal growths or tumors that originate within the thorax, encompassing malignant (cancerous) and benign (non-cancerous) forms, which can affect structures such as the lungs, pleura, mediastinum, and chest wall.
The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition.
A malignant tumor composed of more than one type of neoplastic tissue. (Dorland, 27th ed)
Neoplasms of the brain and spinal cord derived from glial cells which vary from histologically benign forms to highly anaplastic and malignant tumors. Fibrillary astrocytomas are the most common type and may be classified in order of increasing malignancy (grades I through IV). In the first two decades of life, astrocytomas tend to originate in the cerebellar hemispheres; in adults, they most frequently arise in the cerebrum and frequently undergo malignant transformation. (From Devita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2013-7; Holland et al., Cancer Medicine, 3d ed, p1082)
Hamartoneoplastic malformation syndrome of uncertain etiology characterized by partial GIGANTISM of the hands and/or feet, asymmetry of the limbs, plantar hyperplasia, hemangiomas (HEMANGIOMA), lipomas (LIPOMA), lymphangiomas (LYMPHANGIOMA), epidermal NEVI; MACROCEPHALY; cranial HYPEROSTOSIS, and long-bone overgrowth. Joseph Merrick, the so-called "elephant man", apparently suffered from Proteus syndrome and not NEUROFIBROMATOSIS, a disorder with similar characteristics.
A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
Tumors of the iris characterized by increased pigmentation of melanocytes. Iris nevi are composed of proliferated melanocytes and are associated with neurofibromatosis and malignant melanoma of the choroid and ciliary body. Malignant melanoma of the iris often originates from preexisting nevi.
A condition with multiple tumor-like lesions caused either by congenital or developmental malformations of BLOOD VESSELS, or reactive vascular proliferations, such as in bacillary angiomatosis. Angiomatosis is considered non-neoplastic.
A delicate membrane enveloping the brain and spinal cord. It lies between the PIA MATER and the DURA MATER. It is separated from the pia mater by the subarachnoid cavity which is filled with CEREBROSPINAL FLUID.
The co-inheritance of two or more non-allelic GENES due to their being located more or less closely on the same CHROMOSOME.

Merlin: the neurofibromatosis 2 tumor suppressor. (1/158)

In recent years, it has become clear that the ERMs occupy a crucial position as protein linkers that both respond to and participate in reorganization of membrane-cytoskeletal interactions. With the identification of new binding partners, the ERMs are also implicated in linked regulation of the activities of particular membrane proteins. Thus, they reside at a junction in a complex web of interactions that must respond to stimuli from both outside and inside the cell. As expected from its structural motifs, merlin behaves in a manner similar to the ERM proteins, but with some notable differences. Chief among these is the absence of intramolecular interaction to mask intermolecular interaction domains in isoform 2. The full range of merlin's intermolecular interactions remains to be delineated, but it can be expected from the comparison to ERMs that merlin also sits within a web of interactions that may involve multiple partners and signaling pathways, some of which it shares with the ERMs. Defining merlin's tumor suppressor function will likely require identifying those differences that are peculiarly important in the target cell types of NF2. However, the fact that inactivation of merlin in the mouse by targeted mutagenesis produces a variety of malignant tumors with a high rate of metastasis [33] suggests that merlin's suppression of tumor formation may involve different partners and pathways in different cell types and genetic backgrounds. Consequently, the disruptions due to merlin inactivation in the progression of malignant mesothelioma may represent a tumor suppressor role operating by a different pathway than that in schwannoma or meningioma.  (+info)

Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. (2/158)

BACKGROUND: Some 4%-5% of those who develop vestibular schwannomas have neurofibromatosis type 2 (NF2). Although about 10% of these patients present initially with a unilateral vestibular schwannoma, the risk for a patient with a truly sporadic vestibular schwannoma developing contralateral disease is unknown. METHODS: A United Kingdom survey of 296 patients with NF2 was reviewed for laterality of vestibular schwannoma at presentation and the presence of other NF2 related features. The time to presentation of bilateral disease was calculated for patients presenting with a unilateral tumour. Mutation analysis of the NF2 gene was carried out on all available cases presenting initially with unilateral disease. RESULTS: Of 240 patients with NF2 with vestibular schwannomas, 45 (18%; 32 sporadic, 13 familial) had either a unilateral tumour or delay in detection between the first and contralateral tumours. Among those tested for NF2 mutations, eight of 27 and nine of 13 were identified among sporadic and familial cases respectively. Sporadic cases showed a high female to male ratio and 19 of 32 have not as yet developed a contralateral tumour (mean 4.1 years after diagnosis of the first). Thirteen of 32 sporadic patients developed a contralateral tumour (mean 6.5 years after the first tumour diagnosis, range 0-22 years) compared with 11 of 13 familial patients (mean delay 5 years, range 0-16 years). Seven of the 45 patients had neither a family history of NF2 nor evidence of related tumours at initial presentation (six before the age of 35 years). CONCLUSION: The risk of patients with sporadic unilateral vestibular schwannomata developing a contralateral tumour in the absence of family history or other features of NF2 is low, but those presenting with other neurogenic tumours in addition to vestibular schwannoma are at high risk of harbouring an NF2 mutation in at least a proportion of their somatic cells.  (+info)

Association of lower cranial nerve schwannoma with spinal ependymoma in ? NF2. (3/158)

A 15 year old male, who had earlier been operated for intraspinal intramedullary ependymoma, subsequently developed a right cerebello pontine (CP) angle mass. A diagnosis of right CP angle ependymoma was considered, in view of established histology of previously operated spinal lesion. Histopathological examination of the well defined extra-axial mass, which was attached with ninth cranial nerve, however revealed a schwannoma. A diagnosis of Neurofibromatosis-2 (NF2) is strongly suspected, because of well established fact, that the spinal ependymomas may have association with lower cranial nerve schwannomas in NF2. Cranial and spinal MRI screening for early diagnosis of associated, asymptomatic lesions, in suspected cases of NF2, particularly in children, is recommended.  (+info)

Paediatric presentation of type 2 neurofibromatosis. (4/158)

BACKGROUND: Neurofibromatosis type 2 (NF2) is a highly penetrant autosomal dominant condition predisposing affected individuals to schwannomas and meningiomas. The proportion of children presenting with meningioma or schwannoma who have NF2 is not well described, and neither is the mode of presentation in most children with the inherited disease. AIMS: To determine the frequency of childhood meningioma and schwannoma cases caused by NF2 and the mode of presentation. METHODS: The records of the Manchester Children's Tumour Registry from 1954 were searched for cases of meningioma and schwannoma. Paediatric presentation in a large UK series of NF2 was also studied. RESULTS: 18% (61/334) of patients with NF2 on the UK database presented in the paediatric age group (0-15 years), frequently with the symptoms of an isolated tumour. More than half had no family history to alert the clinician to their susceptibility. Three of 22 children presenting with a meningioma on the Manchester Children's Tumour Registry have gone on to develop classic features of NF2. CONCLUSIONS: Clinicians should suspect NF2 in children presenting with meningioma, schwannoma, and skin features, such as neurofibromas/schwannomas, but fewer than 6 cafe au lait patches, who thus fall short of a diagnosis of neurofibromatosis type 1.  (+info)

Isolated metastases of adenocarcinoma in the bilateral internal auditory meatuses mimicking neurofibromatosis type 2--case report. (5/158)

A 56-year-old male with a history of lung cancer presented with isolated metastases of adenocarcinoma in the bilateral internal auditory meatuses (IAMs), mimicking the bilateral acoustic schwannomas of neurofibromatosis type 2, and manifesting as rapidly worsening tinnitus and bilateral hearing loss. Magnetic resonance imaging showed small tumors in both IAMs with no sign of leptomeningeal metastasis. The preoperative diagnosis was neurofibromatosis type 2. Both tumors were removed and the histological diagnoses were adenocarcinoma. Neuroimaging differentiation of a solitary metastatic IAM tumor from a benign tumor is difficult, although rapidly progressive eighth cranial nerve dysfunction suggests a malignant process. Metastases should be considered as a rare diagnostic possibility in a patient with small tumors in both IAMs.  (+info)

Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations. (6/158)

Despite intense study of the neurofibromatosis type 2 (NF2) tumor-suppressor protein merlin, the biological properties and tumor-suppressor functions of merlin are still largely unknown. In this study, we examined the molecular activities of NF2-causing mutant merlin proteins in transfected mammalian cells, to elucidate the merlin properties that are critical for tumor-suppressor function. Most important, we found that 80% of the merlin mutants studied significantly altered cell adhesion, causing cells to detach from the substratum. This finding implies a function for merlin in regulating cell-matrix attachment, and changes in cell adhesion caused by mutant protein expression may be an initial step in the pathogenesis of NF2. In addition, five different mutations in merlin caused a significant increase in detergent solubility of merlin compared to wild type, indicating a decreased ability to interact with the cytoskeleton. Although not correlated to the cell-adhesion phenotype, four missense mutations decreased the binding of merlin to the ERM-interacting protein EBP-50, implicating this interaction in merlin inhibition of cell growth. Last, we found that some NF2 point mutations in merlin most closely resembled gain-of-function alleles in their cellular phenotype, which suggests that mutant NF2 alleles may not always act in a loss-of-function manner, as had been assumed, but may include a spectrum of allelic types with different phenotypic effects on the function of the protein. In aggregate, these cellular phenotypes provide a useful assay for identifying the functional domains and molecular partners necessary for merlin tumor-suppressor activity.  (+info)

Mutations and allelic loss of the NF2 gene in neurofibromatosis 2-associated skin tumors. (7/158)

Schwannomas in the skin are frequently observed in neurofibromatosis 2 patients. In about one-quarter of the cases, skin tumors are the first clinical symptoms of this disease. Recognizing neurofibromatosis-2-related skin tumors is therefore important for early diagnosis of neurofibromatosis 2, especially in pediatric patients. In this study, we examined 40 skin tumors (36 schwannomas and four neurofibromas) from 20 neurofibromatosis 2 patients for NF2 mutations and allelic loss. NF2 mutations have been identified in blood from 15 (75%) of the 20 patients. We found NF2 mutations in five (13%) and NF2 allelic loss in 18 (45%) of the 40 analyzed tumors. Genetic alterations (allelic loss or mutation) were thus found in 50 (63%) out of the total of 80 examined alleles. In 17 (43%) tumors, alterations were found on both NF2 alleles. These results suggest that, as in the case of vestibular schwannomas and meningiomas, loss of functional NF2 gene product is also the critical event in the development of skin schwannomas. Identification of genetic alterations of the NF2 gene in skin tumors may help to identify neurofibromatosis-2-associated skin tumors, thus assisting in the diagnosis of neurofibromatosis 2 in ambiguous cases, and excluding neurofibromatosis 1 in unclear cases. We also report that the detection rate of constitutional mutations was higher in patients with skin tumors (65%) than in patients without skin tumors (40%).  (+info)

Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. (8/158)

Hemizygosity for the NF2 gene in humans causes a syndromic susceptibility to schwannoma development. However, Nf2 hemizygous mice do not develop schwannomas but mainly osteosarcomas. In the tumors of both species, the second Nf2 allele is inactivated. We report that conditional homozygous Nf2 knockout mice with Cre-mediated excision of Nf2 exon 2 in Schwann cells showed characteristics of neurofibromatosis type 2. These included schwannomas, Schwann cell hyperplasia, cataract, and osseous metaplasia. Thus, the tumor suppressor function of Nf2, here revealed in murine Schwann cells, was concealed in hemizygous Nf2 mice because of insufficient rate of second allele inactivation in this cell compartment. The finding of this conserved function documents the relevance of the present approach to model the human disease.  (+info)

Neurofibromatosis 1 (NF1) is a genetic disorder that affects the development and growth of nerve tissue. It's also known as von Recklinghausen disease. NF1 is characterized by the growth of non-cancerous tumors on the nerves, as well as skin and bone abnormalities.

The symptoms of Neurofibromatosis 1 can vary widely, even among members of the same family. Some common features include:

* Multiple café au lait spots (flat, light brown patches on the skin)
* Freckles in the underarms and groin area
* Benign growths on or under the skin called neurofibromas
* Larger, more complex tumors called plexiform neurofibromas
* Optic gliomas (tumors that form on the optic nerve)
* Distinctive bone abnormalities, such as a curved spine (scoliosis) or an enlarged head (macrocephaly)
* Learning disabilities and behavioral problems

Neurofibromatosis 1 is caused by mutations in the NF1 gene, which provides instructions for making a protein called neurofibromin. This protein helps regulate cell growth and division. When the NF1 gene is mutated, the production of neurofibromin is reduced or absent, leading to uncontrolled cell growth and the development of tumors.

NF1 is an autosomal dominant disorder, which means that a person has a 50% chance of inheriting the mutated gene from an affected parent. However, about half of all cases are the result of new mutations in the NF1 gene, and occur in people with no family history of the disorder.

There is currently no cure for Neurofibromatosis 1, but treatments are available to manage the symptoms and complications of the disease. These may include medications to control pain or reduce the size of tumors, surgery to remove tumors or correct bone abnormalities, and physical therapy to improve mobility and strength. Regular monitoring by a healthcare team experienced in treating Neurofibromatosis 1 is also important to detect any changes in the condition and provide appropriate care.

Neurofibromatosis 2 (NF2) is a genetic disorder characterized by the development of non-cancerous tumors in the nervous system, particularly on the nerves related to hearing and balance. It's also known as central neurofibromatosis or bilateral acoustic neuroma syndrome.

The primary feature of NF2 is the growth of schwannomas, which are tumors that develop from the cells surrounding nerve fibers. These typically grow on the vestibular nerve, leading to hearing loss, ringing in the ears (tinnitus), and balance problems. Bilateral acoustic neuromas (schwannomas affecting both vestibular nerves) are a hallmark of this condition.

Other common features include:

1. Meningiomas: These are tumors that grow in the meninges, the protective layers surrounding the brain and spinal cord.
2. Ependymomas: These are tumors that develop from the ependymal cells lining the ventricles (fluid-filled spaces) in the brain or the spinal cord canal.
3. Neurofibromas: Unlike in Neurofibromatosis type 1, these are less common and typically don't become cancerous.
4. Skin changes: While not as prevalent as in NF1, some people with NF2 may have skin freckles, café-au-lait spots, or skin tumors.
5. Eye problems: Some individuals may experience cataracts, retinal abnormalities, or optic nerve tumors (optic gliomas).
6. Other potential symptoms: Headaches, facial weakness or numbness, and difficulty swallowing or speaking.

NF2 is an autosomal dominant disorder, meaning that a person has a 50% chance of inheriting the condition if one of their parents has it. However, about half of all NF2 cases result from spontaneous genetic mutations with no family history of the disorder.

Neurofibromatosis 1 (NF1) is a genetic disorder caused by mutations in the NF1 gene, which is located on chromosome 17 and encodes the protein neurofibromin. Neurofibromin is a tumor suppressor protein that regulates cell growth and differentiation.

The NF1 gene mutation leads to the development of benign (non-cancerous) tumors on nerves and skin, called neurofibromas, as well as other clinical features such as café-au-lait spots (light brown patches on the skin), freckling in the axillary or inguinal regions, Lisch nodules (harmless growths on the iris of the eye), and skeletal abnormalities.

Neurofibromatosis 1 is an autosomal dominant disorder, which means that a person has a 50% chance of inheriting the mutated gene from an affected parent. However, up to 50% of cases result from new mutations in the NF1 gene and occur in people with no family history of the condition.

The clinical manifestations of Neurofibromatosis 1 can vary widely among individuals, even within the same family. The diagnosis is typically made based on clinical criteria established by the National Institutes of Health (NIH). Treatment is generally focused on managing symptoms and addressing complications as they arise, although surgery may be necessary to remove large or symptomatic tumors.

Neurofibromatosis 2 (NF2) is a genetic disorder characterized by the development of non-cancerous tumors in the nervous system. It is caused by mutations in the NF2 gene, which provides instructions for making a protein called merlin or schwannomin. This protein helps regulate cell growth and plays a role in suppressing tumor formation.

In NF2, the lack of functional merlin protein leads to an increased risk of developing tumors on the nerves related to hearing and balance (vestibular schwannomas or acoustic neuromas), on the spine (schwannomas), and on the brain (meningiomas). These tumors can cause various symptoms, such as hearing loss, ringing in the ears, balance problems, numbness or weakness in the limbs, and visual changes.

NF2 is an autosomal dominant disorder, meaning that a person has a 50% chance of inheriting the mutated gene from an affected parent and developing the condition. However, about half of all NF2 cases result from new mutations in the NF2 gene, with no family history of the disorder.

Neurofibromatoses are a group of genetic disorders that primarily affect the nervous system. The term "neurofibromatosis" is often used to refer to two specific conditions: neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2). These conditions are characterized by the growth of tumors on the nerves, called neurofibromas.

Neurofibromatosis type 1 (NF1): This is the most common form of neurofibromatosis, affecting about 1 in every 3,000 people worldwide. NF1 is caused by mutations in the NF1 gene and is characterized by the development of benign tumors on the nerves called neurofibromas. These tumors can develop anywhere on the body, including the skin, spinal cord, and brain. Other common features of NF1 include:

* Freckles in the underarms and groin area
* Lisch nodules (small, noncancerous growths) on the iris of the eye
* Bone abnormalities, such as scoliosis or bowing of the legs
* Learning disabilities or cognitive impairment

Neurofibromatosis type 2 (NF2): This form of neurofibromatosis is much rarer than NF1, affecting about 1 in every 30,000 people worldwide. NF2 is caused by mutations in the NF2 gene and is characterized by the development of benign tumors on the nerves that transmit sound from the inner ear to the brain (acoustic neuromas). These tumors can cause hearing loss, ringing in the ears, and balance problems. Other common features of NF2 include:

* Multiple schwannomas (tumors that develop on the protective covering of the nerves)
* Meningiomas (tumors that develop in the membranes surrounding the brain and spinal cord)
* Skin tumors called neurofibromas, although these are less common than in NF1

It is important to note that while neurofibromatoses can cause a range of symptoms and complications, most people with these conditions have a normal lifespan. With proper medical care and monitoring, it is possible to manage the symptoms and reduce the risk of complications.

Neurofibromin 1 is a protein that is encoded by the NF1 gene in humans. Neurofibromin 1 acts as a tumor suppressor, helping to regulate cell growth and division. It plays an important role in the nervous system, where it helps to control the development and function of nerve cells. Mutations in the NF1 gene can lead to neurofibromatosis type 1 (NF1), a genetic disorder characterized by the growth of non-cancerous tumors on the nerves (neurofibromas) and other symptoms.

Neurofibromin 2 is not a medical term itself, but Neurofibromin 1 and Neurofibromin 2 are related to a genetic disorder called Neurofibromatosis. Neurofibromin 1 is the correct term, which is a protein encoded by the NF1 gene in humans.

Neurofibromin 1 is a tumor suppressor protein that plays a crucial role in regulating cell growth and differentiation. Mutations in the NF1 gene can lead to Neurofibromatosis type 1 (NF1), a genetic disorder characterized by the development of benign tumors on the nerves, skin, and other parts of the body.

Neurofibromin 2, on the other hand, is not a recognized term in medical literature. It is possible that there is some confusion with Neurofibromatosis type 2 (NF2), which is a separate genetic disorder caused by mutations in the NF2 gene. The NF2 gene encodes a protein called Merlin, which also functions as a tumor suppressor and helps regulate cell growth and division.

Therefore, it is essential to clarify whether you are asking about Neurofibromin 1 or Neurofibromatosis type 2 when using the term "Neurofibromin 2."

A plexiform neurofibroma is a type of neurofibroma, which is a benign tumor that develops from the nerve sheath. In a plexiform neurofibroma, the tumor grows along the nerves and can involve multiple fascicles, leading to a large, diffuse mass. These tumors can occur anywhere in the body but are most commonly found in the head, neck, and trunk.

Plexiform neurofibromas can be associated with neurofibromatosis type 1 (NF1), a genetic disorder that affects approximately 1 in every 3,000 people worldwide. In individuals with NF1, plexiform neurofibromas can cause significant morbidity, including disfigurement, pain, and functional impairment. Additionally, there is a small risk of malignant transformation into a type of cancer called malignant peripheral nerve sheath tumor (MPNST).

The diagnosis of plexiform neurofibromas is typically made based on clinical examination, medical history, and imaging studies such as MRI. A biopsy may be necessary to confirm the diagnosis. Treatment options for plexiform neurofibromas include surgery, radiation therapy, and medication. The choice of treatment depends on several factors, including the size and location of the tumor, the presence of symptoms, and the risk of malignant transformation.

A neurofibroma is a benign (non-cancerous) tumor that develops from the nerve sheath, which is the protective covering around nerves. These tumors can grow anywhere on the body and can be found under the skin or deep inside the body. Neurofibromas can vary in size, and they may cause symptoms such as pain, numbness, or tingling if they press on nearby nerves.

Neurofibromas are a common feature of neurofibromatosis type 1 (NF1), a genetic disorder that affects approximately 1 in every 3,000 people worldwide. NF1 is characterized by the development of multiple neurofibromas and other tumors, as well as skin changes such as café-au-lait spots and freckling.

It's important to note that while most neurofibromas are benign, they can rarely undergo malignant transformation and become cancerous. If you have a neurofibroma or are concerned about your risk of developing one, it's important to seek medical advice from a healthcare professional who is familiar with this condition.

Café-au-lait spots are light to dark brown, flat patches on the skin that are benign and usually harmless. The term "café-au-lait" means "coffee with milk," which describes the color of these spots. They can vary in size from a few millimeters to several centimeters in diameter and can appear anywhere on the body, although they are most commonly found on the trunk and buttocks.

While café-au-lait spots are common and can occur in up to 20% of the general population, having multiple (more than six) such spots, especially if they are large or present at birth, may be a sign of an underlying medical condition, such as neurofibromatosis type 1 (NF1), a genetic disorder that affects the growth and development of nerve tissue.

Therefore, it is essential to monitor café-au-lait spots and report any changes or concerns to a healthcare provider.

An Optic Nerve Glioma is a type of brain tumor that arises from the glial cells (supportive tissue) within the optic nerve. It is most commonly seen in children, particularly those with neurofibromatosis type 1 (NF1). These tumors are typically slow-growing and may not cause any symptoms, especially if they are small. However, as they grow larger, they can put pressure on the optic nerve, leading to vision loss or other visual disturbances. In some cases, these tumors can also affect nearby structures in the brain, causing additional neurological symptoms. Treatment options may include observation, chemotherapy, radiation therapy, or surgery, depending on the size and location of the tumor, as well as the patient's age and overall health.

Nerve sheath neoplasms are a group of tumors that arise from the cells surrounding and supporting the nerves. These tumors can be benign or malignant and include schwannomas, neurofibromas, and malignant peripheral nerve sheath tumors (MPNSTs). Schwannomas develop from the Schwann cells that produce the myelin sheath of the nerve, while neurofibromas arise from the nerve's supporting cells called fibroblasts. MPNSTs are cancerous tumors that can grow rapidly and invade surrounding tissues. Nerve sheath neoplasms can cause various symptoms depending on their location and size, including pain, numbness, weakness, or paralysis in the affected area.

A neurilemmoma, also known as schwannoma or peripheral nerve sheath tumor, is a benign, slow-growing tumor that arises from the Schwann cells, which produce the myelin sheath that surrounds and insulates peripheral nerves. These tumors can occur anywhere along the course of a peripheral nerve, but they most commonly affect the acoustic nerve (vestibulocochlear nerve), leading to a type of tumor called vestibular schwannoma or acoustic neuroma. Neurilemmomas are typically encapsulated and do not invade the surrounding tissue, although larger ones may cause pressure-related symptoms due to compression of nearby structures. Rarely, these tumors can undergo malignant transformation, leading to a condition called malignant peripheral nerve sheath tumor or neurofibrosarcoma.

Optic nerve neoplasms refer to abnormal growths or tumors that develop within or near the optic nerve. These tumors can be benign (non-cancerous) or malignant (cancerous).

Benign optic nerve neoplasms include optic nerve meningiomas and schwannomas, which originate from the sheaths surrounding the optic nerve. They usually grow slowly and may not cause significant vision loss, but they can lead to compression of the optic nerve, resulting in visual field defects or optic disc swelling (papilledema).

Malignant optic nerve neoplasms are rare but more aggressive. The most common type is optic nerve glioma, which arises from the glial cells within the optic nerve. These tumors can quickly damage the optic nerve and cause severe vision loss.

It's important to note that any optic nerve neoplasm requires prompt medical evaluation and treatment, as they can potentially lead to significant visual impairment or even blindness if left untreated.

An acoustic neuroma, also known as vestibular schwannoma, is not actually a neuroma but rather a benign (noncancerous) tumor that develops on the vestibular nerve. This nerve is one of the two nerves that transmit sound and balance information from the inner ear to the brain. The tumor arises from an overproduction of Schwann cells, which normally provide a protective covering for the nerve fibers. As the tumor grows, it can press against the hearing and balance nerves, causing symptoms such as hearing loss, ringing in the ear (tinnitus), unsteadiness, and disequilibrium. In some cases, acoustic neuromas can become quite large and cause additional symptoms by pressing on nearby cranial nerves. Treatment options include observation, radiation therapy, or surgical removal of the tumor.

Peripheral nervous system (PNS) neoplasms refer to tumors that originate in the peripheral nerves, which are the nerves outside the brain and spinal cord. These tumors can be benign or malignant (cancerous). Benign tumors, such as schwannomas and neurofibromas, grow slowly and do not spread to other parts of the body. Malignant tumors, such as malignant peripheral nerve sheath tumors (MPNSTs), can invade nearby tissues and may metastasize (spread) to other organs.

PNS neoplasms can cause various symptoms depending on their location and size. Common symptoms include pain, weakness, numbness, or tingling in the affected area. In some cases, PNS neoplasms may not cause any symptoms until they become quite large. Treatment options for PNS neoplasms depend on several factors, including the type, size, and location of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Neurofibrosarcoma is a rare type of soft tissue sarcoma, which is a cancer that develops in the soft tissues of the body such as fat, muscle, tendons, blood vessels, and nerves. Neurofibrosarcoma specifically arises from the nerve sheath cells, also known as the Schwann cells, that cover and protect the peripheral nerves.

This type of cancer typically forms a painless mass or tumor in the affected area, which can grow and invade nearby tissues and organs over time. Neurofibrosarcoma can occur anywhere in the body but is most commonly found in the arms, legs, trunk, or head and neck region.

Neurofibrosarcoma can be classified into two main types: conventional and malignant peripheral nerve sheath tumor (MPNST). Conventional neurofibrosarcoma is more common and tends to occur in older adults, while MPNST is a more aggressive form that is associated with genetic disorders such as neurofibromatosis type 1.

Treatment for neurofibrosarcoma typically involves surgical removal of the tumor, along with radiation therapy and/or chemotherapy to help prevent recurrence and spread of the cancer. The prognosis for neurofibrosarcoma varies depending on several factors, including the size and location of the tumor, the patient's age and overall health, and the stage of the disease at diagnosis.

Cranial nerve neoplasms refer to abnormal growths or tumors that develop within or near the cranial nerves. These nerves are responsible for transmitting sensory and motor information between the brain and various parts of the head, neck, and trunk. There are 12 pairs of cranial nerves, each with a specific function and location in the skull.

Cranial nerve neoplasms can be benign or malignant and may arise from the nerve itself (schwannoma, neurofibroma) or from surrounding tissues that invade the nerve (meningioma, epidermoid cyst). The growth of these tumors can cause various symptoms depending on their size, location, and rate of growth. Common symptoms include:

* Facial weakness or numbness
* Double vision or other visual disturbances
* Hearing loss or tinnitus (ringing in the ears)
* Difficulty swallowing or speaking
* Loss of smell or taste
* Uncontrollable eye movements or drooping eyelids

Treatment for cranial nerve neoplasms depends on several factors, including the type, size, location, and extent of the tumor, as well as the patient's overall health. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. Regular follow-up care is essential to monitor for recurrence or complications.

Nervous system neoplasms are abnormal growths or tumors that occur within the nervous system, which includes the brain, spinal cord, and peripheral nerves. These tumors can be benign (non-cancerous) or malignant (cancerous), and their growth can compress or infiltrate surrounding tissues, leading to various neurological symptoms. The causes of nervous system neoplasms are not fully understood but may involve genetic factors, exposure to certain chemicals or radiation, and certain viral infections. Treatment options depend on the type, location, and size of the tumor and can include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

A meningioma is a type of slow-growing tumor that forms on the membranes (meninges) surrounding the brain and spinal cord. It's usually benign, meaning it doesn't spread to other parts of the body, but it can still cause serious problems if it grows and presses on nearby tissues.

Meningiomas most commonly occur in adults, and are more common in women than men. They can cause various symptoms depending on their location and size, including headaches, seizures, vision or hearing problems, memory loss, and changes in personality or behavior. In some cases, they may not cause any symptoms at all and are discovered only during imaging tests for other conditions.

Treatment options for meningiomas include monitoring with regular imaging scans, surgery to remove the tumor, and radiation therapy to shrink or kill the tumor cells. The best treatment approach depends on factors such as the size and location of the tumor, the patient's age and overall health, and their personal preferences.

An auditory brainstem implant (ABI) is a surgically placed device that provides a sense of sound to individuals who have severe hearing loss and cannot benefit from cochlear implants. Unlike cochlear implants, which stimulate the auditory nerve directly, ABIs transmit electrical signals directly to the brainstem, bypassing the inner ear entirely.

The ABI consists of a microphone, processor, and a series of electrodes that are surgically placed on the surface of the brainstem. The microphone picks up sounds from the environment, and the processor converts them into electrical signals. These signals are then sent to the electrodes, which stimulate the nearby nerve cells in the brainstem.

The brain interprets these stimuli as sound, allowing the individual to perceive some level of hearing. While ABIs do not provide the same level of hearing as cochlear implants, they can help individuals with profound hearing loss to communicate more effectively and improve their quality of life.

It's important to note that ABIs are typically reserved for individuals who have severe hearing loss due to damage to the inner ear or auditory nerve, and who are not candidates for cochlear implants. The procedure is complex and carries risks, so it is only recommended in cases where the potential benefits outweigh the risks.

A meningocele is a type of neural tube defect that results in the herniation of the meninges (the protective membranes covering the brain and spinal cord) through a defect in the vertebral column. The meninges protrude as a sac-like structure, which may be covered by skin or a thin layer of tissue. Meningoceles usually do not contain neural tissue, but cerebrospinal fluid is present within the sac. They are typically asymptomatic unless there is compression of surrounding structures or infection. Treatment generally involves surgical repair to prevent potential complications such as meningitis or neurological damage.

A hamartoma is a benign tumor-like growth that is composed of an unusual mixture of cells and tissues that are normally found in the affected area. These growths can occur anywhere in the body, but they are most commonly found in the skin, lungs, and brain. Hamartomas are typically slow growing and do not spread to other parts of the body (metastasize). They are usually harmless, but in some cases, they may cause symptoms or complications depending on their size and location. In general, hamartomas do not require treatment unless they are causing problems.

Pseudarthrosis is a medical term that refers to a false joint or a nonunion of bones, meaning that the broken bone ends do not heal properly and continue to move at the fracture site. This condition can cause pain, instability, and deformity in the affected limb. It may require additional treatment such as surgery to promote bone healing and stabilization.

Human chromosome pair 17 consists of two rod-shaped structures present in the nucleus of each human cell. Each chromosome is made up of DNA tightly coiled around histone proteins, forming a complex called chromatin. Chromosomes carry genetic information in the form of genes, which are segments of DNA that contain instructions for the development and function of an organism.

Human cells typically have 23 pairs of chromosomes, for a total of 46 chromosomes. Pair 17 is one of the autosomal pairs, meaning it is not a sex chromosome (X or Y). Chromosome 17 is a medium-sized chromosome and contains an estimated 800 million base pairs of DNA. It contains approximately 1,500 genes that provide instructions for making proteins and regulating various cellular processes.

Chromosome 17 is associated with several genetic disorders, including inherited cancer syndromes such as Li-Fraumeni syndrome and hereditary nonpolyposis colorectal cancer (HNPCC). Mutations in genes located on chromosome 17 can increase the risk of developing various types of cancer, including breast, ovarian, colon, and pancreatic cancer.

Schwann cells, also known as neurolemmocytes, are a type of glial cell that form the myelin sheath around peripheral nervous system (PNS) axons, allowing for the rapid and efficient transmission of nerve impulses. These cells play a crucial role in the maintenance and function of the PNS.

Schwann cells originate from the neural crest during embryonic development and migrate to the developing nerves. They wrap around the axons in a spiral fashion, forming multiple layers of myelin, which insulates the nerve fibers and increases the speed of electrical impulse transmission. Each Schwann cell is responsible for myelinating a single segment of an axon, with the gaps between these segments called nodes of Ranvier.

Schwann cells also provide structural support to the neurons and contribute to the regeneration of injured peripheral nerves by helping to guide the regrowth of axons to their targets. Additionally, Schwann cells can participate in immune responses within the PNS, such as releasing cytokines and chemokines to recruit immune cells during injury or infection.

A learning disorder is a neurodevelopmental disorder that affects an individual's ability to acquire, process, and use information in one or more academic areas despite normal intelligence and adequate instruction. It can manifest as difficulties with reading (dyslexia), writing (dysgraphia), mathematics (dyscalculia), or other academic skills. Learning disorders are not the result of low intelligence, lack of motivation, or environmental factors alone, but rather reflect a significant discrepancy between an individual's cognitive abilities and their academic achievement. They can significantly impact a person's ability to perform in school, at work, and in daily life, making it important to diagnose and manage these disorders effectively.

Noonan Syndrome is a genetic disorder that affects various parts of the body and is characterized by distinctive facial features, short stature, heart defects, and developmental delays. It is caused by mutations in genes responsible for regulating cell growth and division. The syndrome is often identified at birth or in early childhood due to its physical manifestations, which may include widely spaced eyes, low-set ears, a short neck, a broad or webbed neck, chest deformities, and pulmonary valve stenosis. Noonan Syndrome affects both sexes and all races equally, with an estimated prevalence of 1 in 1,000 to 1 in 2,500 live births.

Facial neoplasms refer to abnormal growths or tumors that develop in the tissues of the face. These growths can be benign (non-cancerous) or malignant (cancerous). Facial neoplasms can occur in any of the facial structures, including the skin, muscles, bones, nerves, and glands.

Benign facial neoplasms are typically slow-growing and do not spread to other parts of the body. Examples include papillomas, hemangiomas, and neurofibromas. While these tumors are usually harmless, they can cause cosmetic concerns or interfere with normal facial function.

Malignant facial neoplasms, on the other hand, can be aggressive and invasive. They can spread to other parts of the face, as well as to distant sites in the body. Common types of malignant facial neoplasms include basal cell carcinoma, squamous cell carcinoma, and melanoma.

Treatment for facial neoplasms depends on several factors, including the type, size, location, and stage of the tumor. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches. It is important to seek medical attention promptly if you notice any unusual growths or changes in the skin or tissues of your face.

Mosaicism, in the context of genetics and medicine, refers to the presence of two or more cell lines with different genetic compositions in an individual who has developed from a single fertilized egg. This means that some cells have one genetic makeup, while others have a different genetic makeup. This condition can occur due to various reasons such as errors during cell division after fertilization.

Mosaicism can involve chromosomes (where whole or parts of chromosomes are present in some cells but not in others) or it can involve single genes (where a particular gene is present in one form in some cells and a different form in others). The symptoms and severity of mosaicism can vary widely, depending on the type and location of the genetic difference and the proportion of cells that are affected. Some individuals with mosaicism may not experience any noticeable effects, while others may have significant health problems.

Developmental bone diseases are a group of medical conditions that affect the growth and development of bones. These diseases are present at birth or develop during childhood and adolescence, when bones are growing rapidly. They can result from genetic mutations, hormonal imbalances, or environmental factors such as poor nutrition.

Some examples of developmental bone diseases include:

1. Osteogenesis imperfecta (OI): Also known as brittle bone disease, OI is a genetic disorder that affects the body's production of collagen, a protein necessary for healthy bones. People with OI have fragile bones that break easily and may also experience other symptoms such as blue sclerae (whites of the eyes), hearing loss, and joint laxity.
2. Achondroplasia: This is the most common form of dwarfism, caused by a genetic mutation that affects bone growth. People with achondroplasia have short limbs and a large head relative to their body size.
3. Rickets: A condition caused by vitamin D deficiency or an inability to absorb or use vitamin D properly. This leads to weak, soft bones that can bow or bend easily, particularly in children.
4. Fibrous dysplasia: A rare bone disorder where normal bone is replaced with fibrous tissue, leading to weakened bones and deformities.
5. Scoliosis: An abnormal curvature of the spine that can develop during childhood or adolescence. While not strictly a developmental bone disease, scoliosis can be caused by various underlying conditions such as cerebral palsy, muscular dystrophy, or spina bifida.

Treatment for developmental bone diseases varies depending on the specific condition and its severity. Treatment may include medication, physical therapy, bracing, or surgery to correct deformities and improve function. Regular follow-up with a healthcare provider is essential to monitor growth, manage symptoms, and prevent complications.

Human chromosome pair 22 consists of two rod-shaped structures present in the nucleus of each cell in the human body. Each chromosome is made up of DNA tightly coiled around histone proteins, forming a complex structure called a chromatin.

Chromosome pair 22 is one of the 22 autosomal pairs of human chromosomes, meaning they are not sex chromosomes (X or Y). Chromosome 22 is the second smallest human chromosome, with each arm of the chromosome designated as p and q. The short arm is labeled "p," and the long arm is labeled "q."

Chromosome 22 contains several genes that are associated with various genetic disorders, including DiGeorge syndrome, velocardiofacial syndrome, and cat-eye syndrome, which result from deletions or duplications of specific regions on the chromosome. Additionally, chromosome 22 is the location of the NRXN1 gene, which has been associated with an increased risk for autism spectrum disorder (ASD) and schizophrenia when deleted or disrupted.

Understanding the genetic makeup of human chromosome pair 22 can provide valuable insights into human genetics, evolution, and disease susceptibility, as well as inform medical diagnoses, treatments, and research.

Multiple primary neoplasms refer to the occurrence of more than one primary malignant tumor in an individual, where each tumor is unrelated to the other and originates from separate cells or organs. This differs from metastatic cancer, where a single malignancy spreads to multiple sites in the body. Multiple primary neoplasms can be synchronous (occurring at the same time) or metachronous (occurring at different times). The risk of developing multiple primary neoplasms increases with age and is associated with certain genetic predispositions, environmental factors, and lifestyle choices such as smoking and alcohol consumption.

Piebaldism is a rare genetic disorder characterized by the presence of white patches of skin and hair due to a lack of melanin, the pigment that gives color to skin, hair, and eyes. These patches are present from birth and typically involve the forehead, chin, and midline of the body. The condition is caused by mutations in the KIT or SLC45A2 genes and is usually inherited in an autosomal dominant pattern, meaning only one copy of the altered gene is needed to cause the disorder. Piebaldism is not harmful to a person's overall health, but it can have significant psychological effects due to its impact on appearance.

Pheochromocytoma is a rare type of tumor that develops in the adrenal glands, which are triangular-shaped glands located on top of each kidney. These tumors produce excessive amounts of hormones called catecholamines, including adrenaline and noradrenaline. This can lead to a variety of symptoms such as high blood pressure, sweating, headaches, rapid heartbeat, and anxiety.

Pheochromocytomas are typically slow-growing and can be benign or malignant (cancerous). While the exact cause of these tumors is not always known, some genetic factors have been identified that may increase a person's risk. Treatment usually involves surgical removal of the tumor, along with medications to manage symptoms and control blood pressure before and after surgery.

Medical Definition:

Magnetic Resonance Imaging (MRI) is a non-invasive diagnostic imaging technique that uses a strong magnetic field and radio waves to create detailed cross-sectional or three-dimensional images of the internal structures of the body. The patient lies within a large, cylindrical magnet, and the scanner detects changes in the direction of the magnetic field caused by protons in the body. These changes are then converted into detailed images that help medical professionals to diagnose and monitor various medical conditions, such as tumors, injuries, or diseases affecting the brain, spinal cord, heart, blood vessels, joints, and other internal organs. MRI does not use radiation like computed tomography (CT) scans.

Meningeal neoplasms, also known as malignant meningitis or leptomeningeal carcinomatosis, refer to cancerous tumors that originate in the meninges, which are the membranes covering the brain and spinal cord. These tumors can arise primarily from the meningeal cells themselves, although they more commonly result from the spread (metastasis) of cancer cells from other parts of the body, such as breast, lung, or melanoma.

Meningeal neoplasms can cause a variety of symptoms, including headaches, nausea and vomiting, mental status changes, seizures, and focal neurological deficits. Diagnosis typically involves imaging studies (such as MRI) and analysis of cerebrospinal fluid obtained through a spinal tap. Treatment options may include radiation therapy, chemotherapy, or surgery, depending on the type and extent of the tumor. The prognosis for patients with meningeal neoplasms is generally poor, with a median survival time of several months to a year.

Somatostatinoma is a rare type of neuroendocrine tumor that originates from the delta cells (D cells) of the diffuse endocrine system, which are responsible for producing and secreting somatostatin, a hormone that inhibits the release of several other hormones. These tumors can occur in various organs, but they most commonly arise in the pancreas and the small intestine (duodenum).

Somatostatinomas are typically slow-growing and can be functional or nonfunctional. Functional somatostatinomas actively produce and secrete excessive amounts of somatostatin, which can lead to a variety of clinical symptoms due to the inhibition of other hormones' functions. Nonfunctional somatostatinomas do not secrete significant amounts of somatostatin and are often discovered incidentally during imaging studies or when they cause local mass effects.

Common symptoms associated with functional somatostatinomas include diarrhea, abdominal pain, weight loss, fat malabsorption, and steatorrhea (fatty stools). They can also lead to diabetes mellitus due to the inhibition of insulin secretion. Additionally, these tumors may cause symptoms related to hormone deficiencies or the compression of nearby structures, depending on their location.

Diagnosis typically involves imaging studies such as CT scans, MRI, and PET scans, along with biochemical tests to measure somatostatin levels in the blood. A definitive diagnosis usually requires a tissue biopsy or surgical removal of the tumor for histopathological examination. Treatment options include surgery, chemotherapy, radiation therapy, and targeted therapies, depending on the stage and location of the tumor.

Pathologic decalcification is a process that occurs when there is a loss of calcium salts from the bones or teeth. This can lead to weakening and structural damage in the affected area. It is often seen in conditions such as osteoporosis, Paget's disease, and tumors that involve bone. In dental contexts, decalcification can also refer to the loss of minerals from tooth enamel, which can lead to cavities and tooth decay. This is often caused by poor oral hygiene and a diet high in sugars.

A mutation is a permanent change in the DNA sequence of an organism's genome. Mutations can occur spontaneously or be caused by environmental factors such as exposure to radiation, chemicals, or viruses. They may have various effects on the organism, ranging from benign to harmful, depending on where they occur and whether they alter the function of essential proteins. In some cases, mutations can increase an individual's susceptibility to certain diseases or disorders, while in others, they may confer a survival advantage. Mutations are the driving force behind evolution, as they introduce new genetic variability into populations, which can then be acted upon by natural selection.

Pigmentation disorders are conditions that affect the production or distribution of melanin, the pigment responsible for the color of skin, hair, and eyes. These disorders can cause changes in the color of the skin, resulting in areas that are darker (hyperpigmentation) or lighter (hypopigmentation) than normal. Examples of pigmentation disorders include melasma, age spots, albinism, and vitiligo. The causes, symptoms, and treatments for these conditions can vary widely, so it is important to consult a healthcare provider for an accurate diagnosis and treatment plan.

A Glomus tumor is a rare, benign (non-cancerous) neoplasm that arises from the glomus body, a specialized form of blood vessel found in the skin, particularly in the fingers and toes. These tumors are highly vascular and usually appear as small, blue or red nodules just beneath the nail bed or on the fingertips. They can also occur in other parts of the body such as the stomach, lung, and kidney, but these locations are much less common.

Glomus tumors typically present with symptoms like severe pain, especially when exposed to cold temperatures or pressure. The pain is often described as sharp, stabbing, or throbbing, and it can be debilitating for some individuals. Diagnosis of glomus tumors usually involves a physical examination, imaging studies such as MRI or CT scans, and sometimes biopsy. Treatment options include surgical excision, which is often curative, and in some cases, embolization or sclerotherapy may be used to reduce the blood flow to the tumor before surgery.

The optic chiasm is a structure in the brain where the optic nerves from each eye meet and cross. This allows for the integration of visual information from both eyes into the brain's visual cortex, creating a single, combined image of the visual world. The optic chiasm plays an important role in the processing of visual information and helps to facilitate depth perception and other complex visual tasks. Damage to the optic chiasm can result in various visual field deficits, such as bitemporal hemianopsia, where there is a loss of vision in the outer halves (temporal fields) of both eyes' visual fields.

Adrenal gland neoplasms refer to abnormal growths or tumors in the adrenal glands. These glands are located on top of each kidney and are responsible for producing hormones that regulate various bodily functions such as metabolism, blood pressure, and stress response. Adrenal gland neoplasms can be benign (non-cancerous) or malignant (cancerous).

Benign adrenal tumors are called adenomas and are usually small and asymptomatic. However, some adenomas may produce excessive amounts of hormones, leading to symptoms such as high blood pressure, weight gain, and mood changes.

Malignant adrenal tumors are called adrenocortical carcinomas and are rare but aggressive cancers that can spread to other parts of the body. Symptoms of adrenocortical carcinoma may include abdominal pain, weight loss, and hormonal imbalances.

It is important to diagnose and treat adrenal gland neoplasms early to prevent complications and improve outcomes. Diagnostic tests may include imaging studies such as CT scans or MRIs, as well as hormone level testing and biopsy. Treatment options may include surgery, radiation therapy, chemotherapy, or a combination of these approaches.

Skin neoplasms refer to abnormal growths or tumors in the skin that can be benign (non-cancerous) or malignant (cancerous). They result from uncontrolled multiplication of skin cells, which can form various types of lesions. These growths may appear as lumps, bumps, sores, patches, or discolored areas on the skin.

Benign skin neoplasms include conditions such as moles, warts, and seborrheic keratoses, while malignant skin neoplasms are primarily classified into melanoma, squamous cell carcinoma, and basal cell carcinoma. These three types of cancerous skin growths are collectively known as non-melanoma skin cancers (NMSCs). Melanoma is the most aggressive and dangerous form of skin cancer, while NMSCs tend to be less invasive but more common.

It's essential to monitor any changes in existing skin lesions or the appearance of new growths and consult a healthcare professional for proper evaluation and treatment if needed.

Thoracic neoplasms refer to abnormal growths or tumors that develop in the thorax, which is the area of the body that includes the chest and lungs. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Malignant thoracic neoplasms are often referred to as lung cancer, but they can also include other types of cancer such as mesothelioma, thymoma, and esophageal cancer.

Thoracic neoplasms can cause various symptoms depending on their location and size. Common symptoms include coughing, chest pain, shortness of breath, hoarseness, and difficulty swallowing. Treatment options for thoracic neoplasms depend on the type, stage, and location of the tumor, as well as the patient's overall health. Treatment may include surgery, radiation therapy, chemotherapy, targeted therapy, or a combination of these approaches.

I must clarify that the term "pedigree" is not typically used in medical definitions. Instead, it is often employed in genetics and breeding, where it refers to the recorded ancestry of an individual or a family, tracing the inheritance of specific traits or diseases. In human genetics, a pedigree can help illustrate the pattern of genetic inheritance in families over multiple generations. However, it is not a medical term with a specific clinical definition.

A "mixed tumor, malignant" is a rare and aggressive type of cancer that contains two or more different types of malignant tissue. It is also known as a "malignant mixed Mullerian tumor" (MMMT) or "carcinosarcoma." This type of tumor most commonly arises in the female reproductive organs, such as the uterus or ovaries, but can also occur in other parts of the body.

The malignant mixed Mullerian tumor is composed of both epithelial and mesenchymal components, which are two different types of tissue. The epithelial component is made up of cancerous glandular or squamous cells, while the mesenchymal component consists of cancerous connective tissue, such as muscle, fat, or bone.

Mixed tumors, malignant can be aggressive and have a high risk of recurrence and metastasis. Treatment typically involves surgical removal of the tumor, followed by radiation therapy and/or chemotherapy to kill any remaining cancer cells. The prognosis for mixed tumors, malignant varies depending on several factors, including the size and location of the tumor, the stage of the disease at diagnosis, and the patient's overall health.

Astrocytoma is a type of brain tumor that arises from astrocytes, which are star-shaped glial cells in the brain. These tumors can occur in various parts of the brain and can have different grades of malignancy, ranging from low-grade (I or II) to high-grade (III or IV). Low-grade astrocytomas tend to grow slowly and may not cause any symptoms for a long time, while high-grade astrocytomas are more aggressive and can grow quickly, causing neurological problems.

Symptoms of astrocytoma depend on the location and size of the tumor but may include headaches, seizures, weakness or numbness in the limbs, difficulty speaking or swallowing, changes in vision or behavior, and memory loss. Treatment options for astrocytomas include surgery, radiation therapy, chemotherapy, or a combination of these approaches. The prognosis for astrocytoma varies widely depending on the grade and location of the tumor, as well as the age and overall health of the patient.

Proteus Syndrome is a rare genetic disorder characterized by progressive overgrowth of skin, bones, muscles, and other tissues. It is caused by a mutation in the AKT1 gene, which regulates cell growth and division. The disorder is named after the Greek sea-god Proteus, who could change his shape at will, as people with this condition often have highly variable and asymmetric features.

The symptoms of Proteus Syndrome can vary widely from person to person, but may include:

1. Overgrowth of skin, which can lead to the formation of thickened, rough, or irregular areas of skin (known as "cerebriform" skin) and deep creases or folds.
2. Asymmetric overgrowth of bones, muscles, and other tissues, leading to differences in size and shape between the two sides of the body.
3. The formation of benign tumors (such as lipomas and lymphangiomas) and abnormal blood vessels.
4. Abnormalities of the brain, eyes, and other organs.
5. Increased risk of developing certain types of cancer.

Proteus Syndrome is typically diagnosed based on a combination of clinical features, medical imaging, and genetic testing. There is no cure for the disorder, but treatment is focused on managing symptoms and preventing complications. This may involve surgery to remove tumors or correct bone deformities, physical therapy to improve mobility and strength, and medications to control pain and other symptoms.

Juvenile Myelomonocytic Leukemia (JMML) is a rare and aggressive type of childhood leukemia, characterized by the overproduction of myeloid and monocytic white blood cells in the bone marrow. These cells accumulate in the bloodstream, leading to an increased risk of infection, anemia, and bleeding. JMML is different from other types of leukemia because it involves both the myeloid and monocytic cell lines, and it often affects younger children, typically those under 4 years old. The exact cause of JMML is not fully understood, but it has been linked to genetic mutations in certain genes, such as PTPN11, NRAS, KRAS, CBL, and NF1. Treatment for JMML usually involves a combination of chemotherapy, stem cell transplantation, and supportive care.

X-ray computed tomography (CT or CAT scan) is a medical imaging method that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional (tomographic) images (virtual "slices") of the body. These cross-sectional images can then be used to display detailed internal views of organs, bones, and soft tissues in the body.

The term "computed tomography" is used instead of "CT scan" or "CAT scan" because the machines take a series of X-ray measurements from different angles around the body and then use a computer to process these data to create detailed images of internal structures within the body.

CT scanning is a noninvasive, painless medical test that helps physicians diagnose and treat medical conditions. CT imaging provides detailed information about many types of tissue including lung, bone, soft tissue and blood vessels. CT examinations can be performed on every part of the body for a variety of reasons including diagnosis, surgical planning, and monitoring of therapeutic responses.

In computed tomography (CT), an X-ray source and detector rotate around the patient, measuring the X-ray attenuation at many different angles. A computer uses this data to construct a cross-sectional image by the process of reconstruction. This technique is called "tomography". The term "computed" refers to the use of a computer to reconstruct the images.

CT has become an important tool in medical imaging and diagnosis, allowing radiologists and other physicians to view detailed internal images of the body. It can help identify many different medical conditions including cancer, heart disease, lung nodules, liver tumors, and internal injuries from trauma. CT is also commonly used for guiding biopsies and other minimally invasive procedures.

In summary, X-ray computed tomography (CT or CAT scan) is a medical imaging technique that uses computer-processed combinations of many X-ray images taken from different angles to produce cross-sectional images of the body. It provides detailed internal views of organs, bones, and soft tissues in the body, allowing physicians to diagnose and treat medical conditions.

Iris neoplasms refer to abnormal growths or tumors that develop in the iris, which is the colored part of the eye. These neoplasms can be benign (non-cancerous) or malignant (cancerous). Benign iris neoplasms are typically slow-growing and do not spread to other parts of the body. Malignant iris neoplasms, on the other hand, can grow quickly and may spread to other parts of the eye or nearby structures, such as the ciliary body or choroid.

Iris neoplasms can cause various symptoms, including changes in the appearance of the eye, such as a visible mass or discoloration, pain, redness, light sensitivity, blurred vision, or changes in the size or shape of the pupil. The diagnosis of iris neoplasms typically involves a comprehensive eye examination, including a visual acuity test, refraction, slit-lamp examination, and sometimes imaging tests such as ultrasound or optical coherence tomography (OCT).

Treatment options for iris neoplasms depend on the type, size, location, and severity of the tumor. Small, benign iris neoplasms may not require treatment and can be monitored over time. Larger or malignant iris neoplasms may require surgical removal, radiation therapy, or other treatments to prevent complications or spread to other parts of the eye or body. It is essential to seek medical attention promptly if you experience any symptoms of iris neoplasms or notice any changes in your vision or the appearance of your eyes.

Angiomatosis is a medical term that refers to a benign condition characterized by the proliferation of blood vessels in various tissues and organs. It is typically composed of small, tangled blood vessels called capillaries, which can form clusters or networks. The condition can affect skin, internal organs, bones, and other tissues.

Angiomatosis is often asymptomatic and may be discovered incidentally during medical imaging or surgical procedures. In some cases, it may cause symptoms such as pain, swelling, or bleeding, depending on the location and extent of the lesions.

While angiomatosis is generally a benign condition, in rare cases, it can be associated with malignant tumors or other medical conditions. Treatment options for angiomatosis depend on the size, location, and symptoms of the lesions and may include observation, medication, or surgical removal.

The arachnoid is one of the three membranes that cover the brain and the spinal cord, known as the meninges. It is located between the dura mater (the outermost layer) and the pia mater (the innermost layer). The arachnoid is a thin, delicate membrane that is filled with cerebrospinal fluid, which provides protection and nutrition to the central nervous system.

The arachnoid has a spider-web like appearance, hence its name, and it is composed of several layers of collagen fibers and elastic tissue. It is highly vascularized, meaning that it contains many blood vessels, and it plays an important role in regulating the flow of cerebrospinal fluid around the brain and spinal cord.

In some cases, the arachnoid can become inflamed or irritated, leading to a condition called arachnoiditis. This can cause a range of symptoms, including pain, muscle weakness, and sensory changes, and it may require medical treatment to manage.

Genetic linkage is the phenomenon where two or more genetic loci (locations on a chromosome) tend to be inherited together because they are close to each other on the same chromosome. This occurs during the process of sexual reproduction, where homologous chromosomes pair up and exchange genetic material through a process called crossing over.

The closer two loci are to each other on a chromosome, the lower the probability that they will be separated by a crossover event. As a result, they are more likely to be inherited together and are said to be linked. The degree of linkage between two loci can be measured by their recombination frequency, which is the percentage of meiotic events in which a crossover occurs between them.

Linkage analysis is an important tool in genetic research, as it allows researchers to identify and map genes that are associated with specific traits or diseases. By analyzing patterns of linkage between markers (identifiable DNA sequences) and phenotypes (observable traits), researchers can infer the location of genes that contribute to those traits or diseases on chromosomes.

Neurofibromatoses in clinical practice. Springer, 2011. "Neurofibromatosis Type 2: eMedicine Radiology". 2016-09-26. Retrieved ... Neurofibromatosis type II (NF2 or NF II) is caused by mutations of the "Merlin" gene, which seems to influence the form and ... Neurofibromatosis type II (also known as MISME syndrome - multiple inherited schwannomas, meningiomas, and ependymomas) is a ... 2021). "Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis". Int J Mol ...
The types of neurofibromatosis are: Neurofibromatosis type I, in which the nerve tissue grows tumors (neurofibromas) that may ... The three types are neurofibromatosis type I (NF1), neurofibromatosis type II (NF2), and schwannomatosis. In NF1 symptoms ... Figure of various morbidities associated with neurofibromatosis type II. The three types of Neurofibromatosis are caused by ... ISBN 978-1-60714-653-7. "Neurofibromatosis. What is neurofibromatosis? Type 1 (NF1) , Patient". Patient. Archived from the ...
Living with Neurofibromatosis Type 1: A Guide for Adults. New York, NY: The National Neurofibromatosis Foundation, Inc. Print. ... Neurofibromatosis type II Characteristics of syndromic ASD conditions - Source for main symptoms: "Neurofibromatosis". Mayo ... "About Neurofibromatosis". Genome.gov. Retrieved 2020-03-05. "Neurofibromatosis: Conference Statement". Archives of Neurology. ... Neurofibromatosis type I (NF-1), or von Recklinghausen syndrome, is a complex multi-system human disorder caused by the ...
Wertelecki, W; Superneau, D. W; Blackburn, W. R; Varakis, J. N (1982). "Neurofibromatosis, skin hemangiomas, and arterial ... Neurofibromatosis 2. Eds., Cohen, B.R. Korf, B.H., Pugh, J.N., The National Neurofibromatosis Foundation, Inc., New York, NY ( ... "Neurofibromatosis 2: Clinical and DNA Linkage Studies of a Large Kindred". New England Journal of Medicine. 319 (5): 278-83. ... 2019 Feb;143(2). pii: e20182399. doi:10.1542/peds.2018-2399. Epub 2019 Jan 4. PubMed PMID 30610099; PubMed Central PMCID: ...
Evans DG, Sainio M, Baser ME (December 2000). "Neurofibromatosis type 2". Journal of Medical Genetics. 37 (12): 897-904. doi: ... 205 (2): 1201-5. doi:10.1006/bbrc.1994.2793. PMID 7802651. Wu S, Huang J, Dong J, Pan D (August 2003). "hippo encodes a Ste-20 ... 18 (2): 309-16. doi:10.1016/j.devcel.2009.12.013. PMID 20159600. Pan D (October 2010). "The hippo signaling pathway in ... Misshapen (Msn, MAP4K4/6/7 in mammals) and Happyhour (Hppy, MAP4K1/2/3/5 in mammals) act in parallel to Hpo to activate Wts. ...
Neurofibromatosis Type 2 (NF-2) Group of inherited disorders in which noncancerous tumors grow on several nerves that usually ... Neurofibromatosis Type 1 (NF-1 von Recklinghausen's) Group of inherited disorders in which noncancerous tumors grow on several ... sometimes called vestibular schwannoma). Also see Neurofibromatosis Type 2. Acquired deafness Loss of hearing that occurs or ... The symptoms of NF-2 include tumors on the hearing nerve which can affect hearing and balance. NF-2 may occur in the teenage ...
Von Recklinghausen Neurofibromatosis. N Engl J Med 1981;305:1617-27). These nodules are found in neurofibromatosis type 1, and ... They can rarely be seen in neurofibromatosis type 2. Glaucoma Watson syndrome Kumar, Vinay; Fausto, Nelson; Fausto, Nelso; ... Markers of neurofibromatosis 1 and immunohistochemical references for neuroectodermal differentiation", Hautarzt, 48 (1): 38-41 ... "Lisch Nodules in Neurofibromatosis Type 2". Archives of Ophthalmology. 107 (11): 1571-1572. doi:10.1001/archopht. ...
Scottish surgeon John Henry Wishart gives the first description in England of neurofibromatosis type II. Navier-Stokes ... ISBN 0-486-69213-2. Retrieved 2010-09-06. Wishart, J. H. (1822-07-01). "Case of Tumours in the Skull, Dura Mater, and Brain". ... Ramsden, R. T.; Birch, J. M.; Evans, D. G. R. (1999-12-01). "Paediatric presentation of type 2 neurofibromatosis". Archives of ... Copley Medal: William Buckland January 2 - Rudolf Clausius, German physicist (died 1888) January 6 - Heinrich Schliemann, ...
"Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies". ... Wishart's name is given to one of the two forms of type 2 neurofibromatosis, the Wishart phenotype, which is seen in young ... Ramsden, R. T.; Birch, J. M.; Evans, D. G. R. (1 December 1999). "Paediatric presentation of type 2 neurofibromatosis". ... reference 2:17ZW503 "Foxhall, (Todshaugh) (LB27051)". portal.historicenvironment.scot. Retrieved 8 September 2019. "OrnaVerum ...
In humans, it is a tumor suppressor protein involved in neurofibromatosis type II. Sequence data reveal its similarity to the ... den Bakker MA, Vissers KJ, Molijn AC, Kros JM, Zwarthoff EC, van der Kwast TH (1999). "Expression of the neurofibromatosis type ... Mutations of the NF2 gene cause a human autosomal dominant disease called neurofibromatosis type 2. It is characterized by the ... Shimizu T, Seto A, Maita N, Hamada K, Tsukita S, Tsukita S, Hakoshima T (2002). "Structural basis for neurofibromatosis type 2 ...
Until 2018, ABI was only indicated for patients with Neurofibromatosis Type 2 (NF2). NF2 is a genetic disorder that is ... for patients with neurofibromatosis type 2 (NF2). House's original ABI consisted of two ball electrodes that were implanted ... and in patients with neurofibromatosis type II. The auditory brainstem implant was first developed in 1979 by William F. House ... "Auditory brainstem implants for neurofibromatosis type 2". Curr Opin Otolaryngol Head Neck Surg. 20 (5): 353-7. doi:10.1097/MOO ...
Ms Jessica Helen Cook, Founding Director, Can You Hear Us? For voluntary services to Neurofibromatosis Type 2 Patients. Lowri ... Warrant Officer Class 2 Jason Liddy, Small Arms School Corps. Major Joel Thomas Malpas, Army Air Corps. Major Jonathon Mark ... Warrant Officer Class 2 Andrew Ian Halliday, Royal Army Physical Training Corps, Army Reserve. Major John Edward Mead Carey- ... Warrant Officer Class 2 Craig John Rutter, The Yorkshire Regiment, Army Reserve. Warrant Officer Class 2 Darren Sobey, Royal ...
Neill GW, Crompton MR (2001). "Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a ... Scoles DR, Huynh DP, Morcos PA, Coulsell ER, Robinson NG, Tamanoi F, Pulst SM (1998). "Neurofibromatosis 2 tumour suppressor ... "Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a novel site in beta-fodrin is ... "A novel isoform of beta-spectrin II localizes to cerebellar Purkinje-cell bodies and interacts with neurofibromatosis type 2 ...
There are many genetic factors associated with intradural tumors, most commonly neurofibromatosis 1 (NF1), neurofibromatosis 2 ... Neurofibromas are associated with neurofibromatosis 1 (NF1). Meningiomas and schwannomas are associated with neurofibromatosis ... 19 (2): 262-6. doi:10.1016/j.jocn.2011.05.021. PMID 22099075. S2CID 11919425. Hamamoto, Yasushi; Kataoka, M.; Senba, T.; Uwatsu ... Jennelle, Richard L. S.; Vijayakumar, Vani; Vijayakumar, Srinivasan (2 August 2011). "A Systemic and Evidence-Based Approach to ...
Children with certain hereditary diseases, such as neurofibromatosis type II (NF2), have been found to be more frequently ... A number of genetic syndromes are associated with the development of ependymoma, including neurofibromatosis type II (NF2), ... "Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas". Cancer Research. 54 (1): 45-7. PMID 8261460. ... 3.0.CO;2-C. PMID 10451703. Ward, S; Harding, B; Wilkins, P; Harkness, W; Hayward, R; Darling, JL; Thomas, DG; Warr, T (2001). " ...
Neurofibromatoses in clinical practice. Springer, 2011. Westhout FD, Mathews M, Paré LS, Armstrong WB, Tully P, Linskey ME ( ... Schwannomatosis is an extremely rare genetic disorder closely related to the more-common disorder neurofibromatosis (NF). ... Schwannomas occur instead of the neurofibromas that are hallmarks of neurofibromatosis Type 1 (NF1). Multiple schwannomas ... sometimes called neurofibromatosis type III). Schwann cells are glial cells that myelinate the axons of nerve cells. Myelin is ...
For example, FRAX1036 differentially inhibits PAK2 and PAK1 activities; FRAX597 suppresses PAK2 activity in neurofibromatosis ... inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas". The Journal of Biological Chemistry. 288 (40 ... 3.3.co;2-n. PMID 9712143. Chan WH, Yu JS, Yang SD (March 1999). "PAK2 is cleaved and activated during hyperosmotic shock- ... Serine/threonine-protein kinase PAK 2 is an enzyme that in humans is encoded by the PAK2 gene. PAK2 is one of three members of ...
January 2021). "Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial". Nature Medicine. ... and neurofibromatosis type 1. "Cabozantinib Use During Pregnancy". Drugs.com. 30 March 2020. Retrieved 23 September 2020. " ... Cabozantinib is a substrate of CYP3A4 and multidrug resistance-associated protein 2; drugs that inhibit these enzymes will ... "Search Orphan Drug Designations and Approvals". U.S. Food and Drug Administration (FDA). 2 March 2017. Retrieved 11 November ...
Drouet A (Dec 2011). "Neurofibromatoses : quel risque épileptique ?" [Seizures in neurofibromatosis. What is the risk?]. Rev ... The disease may be either sporadic or associated with neurofibromatosis type 2. The lesion is usually focused in one place, ... "Meningioangiomatosis without neurofibromatosis simulating encephalitis in neuroimaging". Surgical Neurology International. 3: ...
Neurofibromatosis is caused by point mutations in the Neurofibromin 1 or Neurofibromin 2 gene. Sickle-cell anemia is caused by ... "Somatic NF1 mutation spectra in a family with neurofibromatosis type 1: Toward a theory of genetic modifiers". Human Mutation. ... 273 (2): 125-32. doi:10.1111/j.1574-6968.2007.00812.x. PMID 17610516. Fudal I, Ross S, Brun H, et al. (August 2009). "Repeat- ... 1 (2): 87-105. doi:10.1016/S0022-2836(59)80038-3. "Genetics Primer". Archived from the original on 11 April 2005. Davies H, ...
"Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients". Otology ... Retrieved 2 August 2019. Berenson A (15 February 2006). "A Cancer Drug Shows Promise, at a Price That Many Can't Pay". The New ... 2 August 2009. Archived from the original on 30 September 2010. "FDA Gives Roche's Avastin the Go-Ahead for Metastatic Renal ... Retrieved 2 June 2016. Velcheti V, Viswanathan A, Govindan R (June 2006). "The proportion of patients with metastatic non-small ...
Scoles DR, Huynh DP, Chen MS, Burke SP, Gutmann DH, Pulst SM (July 2000). "The neurofibromatosis 2 tumor suppressor protein ... Scoles DR, Huynh DP, Chen MS, Burke SP, Gutmann DH, Pulst SM (2000). "The neurofibromatosis 2 tumor suppressor protein ... 277 (2): 1031-9. doi:10.1074/jbc.M109992200. PMID 11687594. Bishop N, Horman A, Woodman P (2002). "Mammalian class E vps ... 213 (1-2): 125-32. doi:10.1016/S0378-1119(98)00184-X. PMID 9630564. "Entrez Gene: HGS hepatocyte growth factor-regulated ...
"Neurofibromatosis 2 tumor suppressor protein colocalizes with ezrin and CD44 and associates with actin-containing cytoskeleton ... 138 (1-2): 171-4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298. Hirao M, Sato N, Kondo T, Yonemura S, Monden M, Sasaki T, ... ICAM-2 molecules regulate spermatid adhesion on Sertoli cell on the apical side of the blood-testis barrier (towards the lumen ... 200 (1-2): 149-56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149. Sainio M, Zhao F, Heiska L, Turunen O, den Bakker M, ...
... most common microdeletion syndrome Prader-Willi syndrome Angelman syndrome Neurofibromatosis type I Neurofibromatosis type II ... "NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype". Human Mutation. 31 (6): E1506-18. doi:10.1002/humu ... "Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2". Nature. 363 (6429 ... doi:10.1007/s00439-004-1219-2. PMID 15565282. S2CID 23190709. Pasmant, E; Sabbagh, A; Spurlock, G; Laurendeau, I; Grillo, E; ...
Neurofibromatosis): Case report: P.C. Karmacharya, S. Koirala, M.P. Upadhyay J. Inst. Med. P. 113 3. Xeroderma pigmentosa: ... 1. Thesis: Lipoprotein Profile in Hypertensive Retinopathy - 1985 2. Investigator: Epidemiology and Microbiology of Corneal ...
doi:10.1136/jmg.2006.045906 Ferner, Rosalie E. "Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective ... "Guidelines for the diagnosis and management of individuals with neurofibromatosis 1." Journal of medical genetics 44, no. 2 ( ... "International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis 1." Cancer research 62, no. ...
"Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein merlin and the ERM protein ezrin". J ... Ezrin also known as cytovillin or villin-2 is a protein that in humans is encoded by the EZR gene. The N-terminus of ezrin ... 112 (2): 165-176. doi:10.1111/j.1365-2567.2004.01882.x. PMC 1782489. PMID 15147559. Serrador JM, Nieto M, Alonso-Lebrero JL, ... 46 (2): 165-86. doi:10.1016/S1040-8428(02)00172-5. PMID 12711360. v t e (Articles with short description, Short description ...
People with neurofibromatosis type 2 (NF-2) have a 50% chance of developing one or more meningiomata.[citation needed] Ninety- ... The most frequent genetic mutations (~50%) involved in meningiomata are inactivation mutations in the neurofibromatosis 2 gene ... and neurofibromatosis type 2. They appear to be able to form from a number of different types of cells including arachnoid ... 114 (2): 249-256. doi:10.1002/ijc.20733. PMID 15540215. Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW (May 2008). " ...
Others such as neurofibromatosis type 1 and 2 as well as tuberous sclerosis complex can potentially be mosaics but may not be. ... Neurofibromatosis type 1 is the most common phakomatosis and it affects approximately 1 in 2500-3000 live births. It is a ... Neurofibromatosis type 2 is an autosomal dominant condition that affects approximately 1 in 35,000-40,000 people. It is caused ... In most instances, neurofibromatosis type 1 can be diagnosed clinically according to consensus criteria and genetic testing is ...
Since infancy, Elchonon Hellinger has suffered from Neurofibromatosis Type 2, which causes the continuous growth of benign ...
Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. Explore ... Some people with neurofibromatosis type 2 also develop clouding of the lens (cataracts. ) in one or both eyes, often beginning ... Neurofibromatosis 2. Otolaryngol Clin North Am. 2012 Apr;45(2):315-32, viii. doi: 10.1016/j.otc.2011.12.005. Citation on PubMed ... Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. The most ...
In contrast to neurofibromatosis type 1 (NF1), NF2 produces a paucity of cutaneous manifestations. ... or neurofibromatosis type 2 (NF2), is a genetic disorder marked by the predisposition to develop a variety of tumors of the ... Central neurofibromatosis, or neurofibromatosis type 2 (NF2), is a genetic disorder marked by the predisposition to develop a ... Central neurofibromatosis, or neurofibromatosis type 2 (NF2), is a multisystem genetic disorder associated with bilateral ...
... Surg Neurol. 2000 Apr;53(4):383-89; discussion ... Objective: The clinical course of bilateral acoustic tumors associated with neurofibromatosis (NF2) is generally troublesome, ... Methods: The current indications for radiosurgery are 1) a growing tumor less than 30 mm in mean diameter, 2) the ipsilateral ...
Neurofibromatosis 2 -f.jpg. Jason Mayeaux 10/31/2012 Vulvar Skin Colored Lesions Skin Colored Papules and Nodules ...
Neurofibromatosis type 2 (NF2) is a genetic condition caused by a mutation of the NF2 gene predisposing to benign tumor ... Neurofibromatosis Clinic Doctors and Staff. At the UCLA NF Clinic, a team of doctors and other health care professionals works ... Neurofibromatosis California. NF Californias goal is to create a community of support for individuals and families affected by ... The Neurofibromatosis Tumor Program at UCLA is at the forefront of medical innovation. We are involved in numerous clinical ...
1996) Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet 59: ... 1993) A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 72:791-800. ... Editor-Neurofibromatosis 2 (NF2) is a rare autosomal dominant disease that is characterised by benign nervous system tumours, ... 1993) Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 363:515 ...
We are an online support group for those affected directly or indirectly with Neurofibromatosis type 2. ... Since NF2 is the lesser known form of Neurofibromatosis, The NF2 Crew was established to address this issue. By sharing ... We are an online support group for those affected (directly or indirectly) with Neurofibromatosis type 2.. ...
Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib ... Patients must have a confirmed diagnosis of neurofibromatosis 2 by fulfilling National Institute of Health (NIH) criteria or ... Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular ... 2, uncontrolled atrial fibrillation of any grade or prolonged QTc interval (,480 msec), as patients with these conditions would ...
Neurofibromatosis type 2 (NF2) is a genetic condition characterized by inactivation of the NF2 tumor suppressor gene and the ... Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and ... Neurofibromatosis type 2 (NF2) is characterized by development of bilateral vestibular schwannomas and a subsequent loss of ... Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L ...
Neurofibromatoses in clinical practice. Springer, 2011. "Neurofibromatosis Type 2: eMedicine Radiology". 2016-09-26. Retrieved ... Neurofibromatosis type II (NF2 or NF II) is caused by mutations of the "Merlin" gene, which seems to influence the form and ... Neurofibromatosis type II (also known as MISME syndrome - multiple inherited schwannomas, meningiomas, and ependymomas) is a ... 2021). "Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis". Int J Mol ...
Neurofibromatosis 2 (NF2) is associated with a rare, potentially treatable type of deafness. The hallmark of NF2 is hearing ... 2).7,8 The majority of genetic hearing loss diagnosed in infancy and early childhood is autosomal recessive in inheritance and ... 2 A different rating scale is appropriate for young children, for whom even limited hearing loss can have a great impact on ... One mutation, the 3243 A-to-G transition in the gene MTTL1, has been found in 2% to 6% of individuals with diabetes mellitus in ...
5. Neurofibromatosis is an autosomal dominant disorder, which means that it affects males and females equally and is dominant ( ... 1. Neurofibromatosis (von Recklinghausen disease) was first described in 1882 by the German pathologist, Friedrich Daniel von ... 6. There are two types of neurofibromatosis: type 1 (90 per cent) and type 2 (10 per cent). Neurofibromatosis-1 is found in ... This however has given rise to the common misconception that Neurofibromatosis and "Elephant Man Disease" is one and the same ( ...
Neurofibromatosis Type 2 answers are found in the 5-Minute Clinical Consult powered by Unbound Medicine. Available for iPhone, ... Neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) are neurocutaneous syndromes (phakomatoses). Although they ... "Neurofibromatosis Type 2." 5-Minute Clinical Consult, 27th ed., Wolters Kluwer, 2020. Medicine Central, im.unboundmedicine.com/ ... Neurofibromatosis Type 2. In: Domino FJF, Baldor RAR, Golding JJ, et al, eds. 5-Minute Clinical Consult. Wolters Kluwer; 2020. ...
In contrast to neurofibromatosis type 1 (NF1), NF2 produces a paucity of cutaneous manifestations. ... or neurofibromatosis type 2 (NF2), is a genetic disorder marked by the predisposition to develop a variety of tumors of the ... Central neurofibromatosis, or neurofibromatosis type 2 (NF2), is a genetic disorder marked by the predisposition to develop a ... Central neurofibromatosis, or neurofibromatosis type 2 (NF2), is a multisystem genetic disorder associated with bilateral ...
Neurofibromatosis type 2 (NF2) and schwannomatosis are rare genetic diseases. They often first appear in young adults ... Neurofibromatosis Type 1 (NF1, Von Recklinghausen Disease). Neurofibromatosis type 1 (NF1, Von Recklinghausen disease) is a ... Video: Neurofibromatosis NF1 von Recklinghausen NF2 Schwannomatosis Glioma Tumor Cause Treatment USMLE 3mn 2023, December. ... Neurofibromatosis Type 2 And Schwannomatosis. Video: Neurofibromatosis Type 2 And Schwannomatosis. ...
Neurofibromatosis, also known as NF, is a genetic disorder that affects the growth of nerve tissue. There are two different ... What is the prevalence of Neurofibromatosis?. NF Type 1 is the most common neurofibromatosis. As many as one in every 5,000 men ... The Difference Between Neurofibromatosis Type 1 and Type 2. What are the Symptoms of Neurofibromatosis Type 1?. Symptoms of NF ... How is Neurofibromatosis Type 1 Diagnosed?. According to Healthline, there are two ways that doctors diagnose NF Type 1. The ...
Neurofibromatosis Type 1 (NF1). This is the more common type of neurofibromatosis. Its also called Von Recklinghausens ... Neurofibromatosis Type 1 (NF1) occurs in about 1 in 3,000 to 4,000 babies in the U.S. NF1 is an autosomal dominant disorder. ... Neurofibromatosis Type 2 (NF2). NF2 affects about 1 in 25,000 people. The symptoms usually appear between ages 18 and 22. The ... Neurofibromatosis Type 2 (NF2) is less common, is also an autosomal dominant disorder. It affects about 1 in 25,000 babies in ...
Most people who have Neurofibromatosis Type 2 (NF2) develop benign tumours called vestibular schwannomas (formerly called ... BPNA Keynote Lecture - Prof Rosalie Ferner - Neurofibromatosis 1 in the 21st Century. Neurofibromatosis 1 in the 21st Century ... Neurofibromatosis Type 1 (NF1) What is NF1? How is NF1 diagnosed? How does NF1 affect you? Case Study: Kierans Story Support ... Neurofibromatosis Type 2 (NF2) What is NF2? How is NF2 diagnosed? How does NF2 affect you? Case Study: Emilys Story Support ...
Neurofibromatosis - Best Data Yet on Risks for Cancer Neurofibromatosis - Best Data Yet on Risks for Cancer. Patients with ... Predictors of Mortality in Neurofibromatosis 2Predictors of Mortality in Neurofibromatosis 2. This study examined the effects ... Neurofibromatosis type 1 and attention deficit hyperactivity disorder: a case study and literature review - Miguel CS, Chaim- ... Your NEJM Group Today: Segmental Neurofibromatosis Image, Humor vs. Straight-Forward Education, Washington IM opening (FREE). ...
Longitudinal Performance of Cochlear Implants in Neurofibromatosis Type 2.. Stefanie Seo, Sarek Shen, Andy S Ding, Francis X ... OBJECTIVE: Cochlear implants (CIs) are a well-established treatment modality for hearing loss due to neurofibromatosis type 2 ( ... Cotransporter 2 Inhibitors for the. Treatment of Patients With Heart. Failure. Importance: Only 1 class of glucose-lowering ... sodium-glucose cotransporter 2 (SGLT2) inhibitors-has. been reported to decrease the risk of cardiovascular. events primarily ...
Become a Master of Diagnostic Imaging of Neurofibromatosis Type 2 (NF2) & Other Neurocutaneous Syndromes w/ case-based micro- ... Neurofibromatosis Type 2 (NF2) and Other Neurocutaneous Syndromes. .css-be3mir{margin:0;font-size:14px;color:rgba(255, 255, 255 ...
Cochlear implantation has a limited but definite role in the rehabilitation of certain neurofibromatosis type 2 (NF2) patients ... The Journal of laryngology and otology, vol.113, no.2, pp.161-3, 1999 (SCI-Expanded) ...
Neurofibromatosis is a genetic disorder of the nervous system that can cause tumors to grow on nerves and produce other ... Neurofibromatosis Neurofibromatosis is a genetic disorder of the nervous system that can cause tumors to grow on nerves and ... Neurofibromatosis Treatment. Wake Forest Baptists multidisciplinary approach to the treatment of neurofibromatosis is aimed at ... Neurofibromatosis 2 (NF2) is much less common than NF1 and is characterized by multiple tumors on the cranial and spinal nerves ...
Neurofibromatosis - Etiology, pathophysiology, symptoms, signs, diagnosis & prognosis from the MSD Manuals - Medical ... Diagnosis of all 3 types is clinical ( see Table: Diagnosing Neurofibromatosis Diagnosing Neurofibromatosis ) by detailed ... Symptoms and Signs of Neurofibromatosis Neurofibromatosis type 1 (NF1) Most patients with NF1 are asymptomatic. Some present ... Neurofibromatosis (Café-au-Lait Spots and Neurofibromas). This patient with neurofibromatosis type 1 has multiple café-au-lait ...
Neurofibromatosis type 2 - with multiple meningiomas (Radiopaedia 38271-40296 3D FIESTA-C). From NC Commons ... Retrieved from "https://nccommons.org/w/index.php?title=Neurofibromatosis_type_2_-_with_multiple_meningiomas_(Radiopaedia_38271 ...
Neurofibromatosis Type 2. 85. 11:00-12:00pm. Laryngology. Andrew Tkaczuk. [email protected]. Laryngology. Assistant Professor. ... Thursday 4/2. 8:00-9:00am. Head & Neck Oncology. Michael Groves. [email protected]. General/Head & Neck. Associate Professor ... 2020, Vol 22 (2). 65-70. Jowett N, Hadlock, TA. A Contemporary Approach to Facial Reanimation. JAMA Facial Plast Surg. 2015, ... 2) Baker, S. Local Flaps in Facial Reconsrtuction, 3rd Edition, 2014, Chapter 18 - Reconstruction of the Nose - (available in ...
Neurofibromatosis Type 2 (NF-2) Group of inherited disorders in which noncancerous tumors grow on several nerves that usually ... Neurofibromatosis Type 1 (NF-1 von Recklinghausens) Group of inherited disorders in which noncancerous tumors grow on several ... sometimes called vestibular schwannoma). Also see Neurofibromatosis Type 2.. Acquired deafness. Loss of hearing that occurs or ... NF-2 may occur in the teenage years with hearing loss. Also see acoustic neurinoma.. Neurogenic communication disorder. ...
Return to Article Details Modern approaches to vestibular schwannomas treatment in patients with neurofibromatosis type 2 using ...
Neurofibromatosis causes tumors to grow on nerves throughout the body and in the brain. Call 314-454-KIDS (5437) for more ... Neurofibromatosis (NF) is a set of complex genetic conditions that can affect nearly every organ system in the body. ... Download our Neurofibromatosis brochure. The Neurofibromatosis Clinical Program is dedicated to combining excellent care for ... We treat both neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2). ...
neurofibromatosis type 1. PN. plexiform neurofibromas. Neurofibromatosis type 1 (NF1; Online Mendelian Inheritance in Man # ... Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials ... Musculoskeletal manifestations of neurofibromatosis type 1. AJR Am J Roentgenol 2012;199:W99-106 doi:10.2214/AJR.11.7811 pmid: ... Neurofibromatosis type 1: spinal manifestations of a systemic disease. J Comput Assist Tomogr 2005;29:532-39 doi:10.1097/01.rct ...

No FAQ available that match "neurofibromatosis 2"

No images available that match "neurofibromatosis 2"